A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice

Vaccine

Volumn 28, Issue 51, 2010, Pages 8085-8094

  Block, Olivia K T ^a   Rodrigo, W W Shanaka I ^a   Quinn, Matthew ^a   Jin, Xia ^a   Rose, Robert C ^a   Schlesinger, Jacob J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Dengue; Domain III; Enhancement; Vaccine

Indexed keywords

CROSS REACTING ANTIBODY; DENGUE VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT DENGUE DOMAIN III PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AEDES ALBOPICTUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG SCREENING; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VACCINES; DENGUE VIRUS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 78649675390     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.004     Document Type: Article

References (45)

1. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
2. Sabin A. Research on dengue during World War II. Am Trop Med Hyg 1952, 1:30-50.
3. Pierson T.C., Fremont D.H., Kuhn R.J., Diamond M.S. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008, 4(3):229-238.
4. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(5):717-725.
5. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
6. Rodenhuis-Zybert I.A., van der Schaar H.M., da Silva Voorham J.M., van der Ende-Metselaar H., Lei H.Y., Wilschut J., et al. Immature dengue virus: a veiled pathogen?. PLoS Pathog 2010, 6(1):e1000718.
7. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007, 81(23):12816-12826.
8. Shrestha B., Brien J.D., Sukupolvi-Petty S., Austin S.K., Edeling M.A., Kim T., et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010, 6(4):e1000823.
9. Lai C.J., Goncalvez A.P., Men R., Wernly C., Donau O., Engle R.E., et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 2007, 81(23):12766-12774.
10. Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009, 4(4):e4991.
11. Wahala W.M., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392(1):103-113.
12. Shanaka W.W., Rodrigo I., Alcena D.C., Rose R.C., Jin X., Schlesinger J.J. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009, 80(1):61-65.
13. Rodrigo W.W., Block O.K., Lane C., Sukupolvi-Petty S., Goncalvez A.P., Johnson S., et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 2009.
14. Rodrigo W.W., Jin X., Blackley S.D., Rose R.C., Schlesinger J.J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006, 80(20):10128-10138.
15. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 2007, 104(22):9422-9427.
16. Kou Z., Quinn M., Chen H., Rodrigo W.W., Rose R.C., Schlesinger J.J., et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 2008, 80(1):134-146.
17. Rose R.C., Bonnez W., Reichman R.C., Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993, 67(4):1936-1944.
18. Rose R.C., Bonnez W., Strike D.G., Reichman R.C. Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J Gen Virol 1990, 71(Pt 11):2725-2729.
19. Rose R.C., Bonnez W., Da Rin C., McCance D.J., Reichman R.C. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994, 75(Pt 9):2445-2449.
20. Russell P.K., Nisalak A., Sukhavachana P., Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99(2):285-290.
21. Halstead S.B., Marchette N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003, 69(6 Suppl):5-11.
22. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007, 2(6):417-426.
23. Coutelier J.P., van der Logt J.T., Heessen F.W., Vink A., van Snick J. Virally induced modulation of murine IgG antibody subclasses. J Exp Med 1988, 168(6):2373-2378.
24. Smucny J.J., Kelly E.P., Macarthy P.O., King A.D. Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein. Am J Trop Med Hyg 1995, 53(4):432-437.
25. Simmons M., Murphy G.S., Kochel T., Raviprakash K., Hayes C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 2001, 65(5):420-426.
26. Gromowski G.D., Barrett N.D., Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 2008, 82(17):8828-8837.
27. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998, 58(5):655-662.
28. Fonseca B.A., Khoshnood K., Shope R.E., Mason P.W. Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene. Am J Trop Med Hyg 1991, 44(5):500-508.
29. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992, 187(2):480-491.
30. Lazo L., Zulueta A., Hermida L., Blanco A., Sanchez J., Valdes I., et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 2009, 52(Pt 4):265-271.
31. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(7):505-517.
32. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 2010, 6(3):e1000821.
33. Brien J.D., Austin S.K., Sukupolvi-Petty S., O'Brien K.M., Johnson S., Fremont D.H., et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 2010, 84(20):10630-10643.
34. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65(2):159-161.
35. Chin J.F., Chu J.J., Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect 2007, 9(1):1-6.
36. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115(1):41-49.
37. Zulueta A., Hermida L., Lazo L., Valdes I., Rodriguez R., Lopez C., et al. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 2003, 308(3):619-626.
38. Jaiswal S., Khanna N., Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif 2004, 33(1):80-91.
39. Zhang Z.S., Yan Y.S., Weng Y.W., Huang H.L., Li S.Q., He S., et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods 2007, 143(2):125-131.
40. Babu J.P., Pattnaik P., Gupta N., Shrivastava A., Khan M., Rao P.V. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 2008, 26(36):4655-4663.
41. Pattnaik P., Babu J.P., Verma S.K., Tak V., Rao P.V. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J Chromatogr B: Analyt Technol Biomed Life Sci 2007, 846(1-2):184-194.
42. Saejung W., Puttikhunt C., Prommool T., Sojikul P., Tanaka R., Fujiyama K., et al. Enhancement of recombinant soluble dengue virus 2 envelope domain III protein production in Escherichia coli trxB and gor double mutant. J Biosci Bioeng 2006, 102(4):333-339.
43. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 2009, 11(2):288-295.
44. Batra G., Raut R., Dahiya S., Kamran N., Swaminathan S., Khanna N. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Methods 2010.
45. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008, 79(3):353-363.